Centogene (CNTGF) AI Stock Analysis

• Market Cap: $2.79M
• Dividend Yield: N/A
• Average Volume (3M): 1.42K
• Price to Earnings (P/E): ―
• Beta (1Y): -3.25
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 493
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical Diagnostics & Screening
• EPS (TTM): N/A
• Shares Outstanding: 29,000,137
• 10 Day Avg. Volume: 1,779
• 30 Day Avg. Volume: 1,424
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 34 Underperform
• Price Target: ―

Centogene's stock is struggling primarily due to poor financial performance, characterized by persistent losses, negative cash flow, and high leverage. Technical analysis points to a bearish trend, and valuation metrics are unattractive with a negative P/E ratio and no dividend yield. The significant drop in stock price post-earnings call further highlights market concerns, resulting in a low overall stock score.

Centogene Business Overview & Revenue Model

Company Description

Centogene NV is a commercial-stage company. It focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. It operates through the following two segments: Pharmaceutical and Diagnostics. The Pharmaceutical segment provides services to pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery and patient monitoring. The Diagnostics segment provides targeted genetic sequencing and diagnostics services. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark.

How the Company Makes Money

Centogene generates revenue primarily through its diagnostic services and collaborations with pharmaceutical companies. The company offers a wide range of genetic testing services, including whole exome and genome sequencing, which are utilized by healthcare providers to diagnose rare hereditary diseases. Additionally, Centogene partners with pharmaceutical companies to support drug development and clinical trials by providing biomarker discovery and patient stratification services. These partnerships often involve long-term contracts and collaborative research agreements, contributing significantly to the company's earnings. Centogene's extensive database of genetic information also provides a valuable resource for research and development, enabling further monetization opportunities through licensing and data-driven projects.

Centogene Financial Statement Overview

Summary

Centogene faces significant financial challenges with persistent losses, negative cash flow, and high leverage. The company demonstrates poor profitability and cash flow performance, alongside a deteriorating balance sheet.

Income Statement

Centogene's revenue growth is stagnant with only a marginal increase in the last year, and the company is struggling with profitability as it reports negative net income consistently. Gross profit margin has decreased significantly compared to earlier years. Both EBIT and EBITDA margins are negative, indicating operational inefficiencies.

Balance Sheet

The company exhibits a high debt-to-equity ratio due to negative equity, indicating potential financial instability. Stockholders' equity has deteriorated significantly, and liabilities exceed assets, raising concerns about solvency. Return on equity is negative, reflecting the company's inability to generate profits from its equity base.

Cash Flow

Operating cash flow has turned negative, and free cash flow is also negative, indicating cash burn. The company has been relying on external financing to cover cash shortfalls. The free cash flow to net income ratio is negative, reflecting poor cash conversion efficiency.

Breakdown	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	―	―	―	―	―
Gross Profit	17.25M	19.76M	28.16M	44.94M	22.77M
EBITDA	-20.48M	-55.30M	-24.73M	-4.93M	-12.09M
Net Income	-35.53M	-63.83M	-92.62M	-21.38M	-20.86M
Balance Sheet
Total Assets	77.16M	92.81M	90.69M	150.13M	117.51M
Cash, Cash Equivalents and Short-Term Investments	―	―	―	―	―
Total Debt	80.73M	60.12M	22.81M	24.10M	26.97M
Total Liabilities	102.44M	88.71M	65.90M	84.35M	58.59M
Stockholders Equity	―	―	―	―	―
Cash Flow
Free Cash Flow	-33.94M	4.00M	-27.23M	-8.09M	-15.35M
Operating Cash Flow	-31.75M	5.23M	-21.70M	8.46M	-7.78M
Investing Cash Flow	―	―	―	―	―
Financing Cash Flow	―	―	―	―	―

Centogene Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.10
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNTGF, the sentiment is Neutral. The current price of 0.1 is above the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.08, and below the 200-day MA of 0.13, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 65.42 is Neutral, neither overbought nor oversold. The STOCH value of 78.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CNTGF.

Centogene Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
QGEN	70 Outperform	9.90B	26.76	10.65%	2.75%	5.15%	412.41%
NTRA	70 Neutral	24.59B	-90.90	-20.32%	―	44.38%	22.87%
FLGT	63 Neutral	681.36M	-13.15	-4.57%	―	4.31%	69.57%
GH	57 Neutral	7.45B	-17.85	135.47%	―	28.74%	18.25%
MYGN	52 Neutral	729.47M	-1.80	-101.83%	―	3.83%	-137.31%
SRPT	48 Neutral	1.82B	-23.64	-4.27%	―	64.89%	-221.56%
CNTGF	34 Underperform	$2.79M	―	140.54%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%